Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

#### Name of entity

#### **Saracen Mineral Holdings Limited**

#### ABN

52 009 215 347

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- <sup>1</sup> +Class of +securities issued or to be issued
- (a) Issue of unvested performance rights
- (b) Issue of ordinary shares
- (c) Lapse of unvested performance rights
- Number of \*securities lapsing issued or to be issued (if known) or maximum number which may be issued
- (a) Issue of 3,274,000 unvested performance rights
- (b) Issue of 22,500 ordinary shares
- (c) Decrease of 173,320 unvested performance rights due to vesting into ordinary shares and lapsing of performance rights
- Principal terms of the 3 +securities (eg, if options, exercise price and expiry date; if \*securities, partly paid the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)
- (a) Issue of unvested performance rights in accordance with terms and conditions of the Company's shareholder approved Long Term Incentive Plan. On vesting each Performance Right is converted into one ordinary share in the Company for nil consideration. Rights will vest in accordance with achievement of the relevant performance hurdles.
- (b) Fully paid ordinary shares.

<sup>+</sup> See chapter 19 for defined terms.

(a) Unvested performance rights are not Do the \*securities rank equally 4 quoted. in all respects from the date of allotment with an existing +class (b) Yes, ordinary shares rank equally with of quoted \*securities? existing fully paid ordinary shares (SAR). If the additional securities do not rank equally, please state: • the date from which they do the extent to which they participate for the next dividend, (in the case of a distribution) trust, interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration (a) and (b) nil consideration (see below). 5 Unvested performance rights represent the Purpose of the issue 6 Incentive Component (If issued as consideration for Long Term the acquisition of assets, clearly remuneration. Vesting of performance rights to a 'good identify those assets) leaver' under the terms and conditions of the Company's Long Term Incentive Plan. No Is the entity an +eligible entity 6a that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed 6c Number of \*securities issued N/A without security holder approval under rule 7.1

under rule 7.1A

6d

Number of \*securities issued N/A

with security holder approval

Appendix 3B Page 2 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 - 122,880,	.354
7	Date of entering *securities into uncertificated holdings or despatch of certificates	(a) Unvested perfor (b) Ordinary shares	rmance rights 9 October 2018 s 15 October 2018
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)	820,271,771	Fully paid ordinary shares (SAR)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the securities in section 2 if applicable)

Number	<sup>+</sup> Class
670,000 335,000 670,000	FY17 Long Term Incentive Plan  Unvested Class A Performance Rights Unvested Class B Performance Rights Unvested Class C Performance Rights  FY18 Long Term Incentive Plan
2,532,615 1,013,046 1,519,569	Unvested Class A Performance Rights Unvested Class B Performance Rights Unvested Class C Performance Rights FY19 Long Term Incentive Plan
818,500 818,500 818,500 818,500	Unvested Class A Performance Rights Unvested Class B Performance Rights Unvested Class C Performance Rights Unvested Class D Performance Rights

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
	CHEIGHEN	

Appendix 3B Page 4 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A

<sup>+</sup> See chapter 19 for defined terms.

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable	N/A
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	<sup>+</sup> Despatch date	N/A
	3 - Quotation of securitie	
34	Type of securities (tick one)	
(a)	Securities described in Part	1
(b)	-	nd of the escrowed period, partly paid securities that become fully paid, en restriction ends, securities issued on expiry or conversion of convertible

## Entities that have ticked box 34(a)

Appendix 3B Page 6 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

## Additional securities forming a new class of securities Tick to indicate you are providing the information or documents If the +securities are +equity securities, the names of the 20 largest holders of the 35 additional \*securities, and the number and percentage of additional \*securities held by those holders If the +securities are +equity securities, a distribution schedule of the additional 36 \*securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over A copy of any trust deed for the additional \*securities 37 Entities that have ticked box 34(b) Number of securities for which 38 N/A <sup>+</sup>quotation is sought N/A 39 Class of \*securities for which quotation is sought N/A Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in

distribution

payment

relation to the next dividend,

or

interest

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and +class of all	N/A	
	<sup>+</sup> securities quoted on ASX		
	(including the securities in clause		

38)

l	N/A	
,		

## **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX. 2
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, 3 action or expense arising from or connected with any breach of the warranties in this agreement.

Appendix 3B Page 8 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 15 October 2018

(Company Secretary)

Print name: Jeremy Ryan

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid <sup>+</sup> ordinary securities on issue 12 months before the <sup>+</sup> issue date or date of agreement to issue	812,848,859	
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> </li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid +ordinary securities cancelled during that 12 month period</li> </ul>	Issue of 5,000,000 ordinary shares on 23 March 2018 – (817,848,859)  Issue of 160,412 ordinary shares on 6 June 2018 – (818,009,271)  Issue of 2,240,000 ordinary shares on 31 July 2018 – (820,249,271)  Issue of 22,500 ordinary shares on 15 October 2018 - (820,271,771)	
"A"	820,271,771	

Appendix 3B Page 10 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	123,040,766
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
• Under an exception in rule 7.2	160,412 ordinary shares
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	160,412
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	123,040,766
Note: number must be same as shown in Step 2	
Subtract "C"	160,412
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	122,880,354
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.